Suspicion of heparin-induced thrombocytopenia in internal medicine: How appropriate is the ordering of anti-PF4/heparin antibody testing?

References

• Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e495–530S
   Web of Science ®Google Scholar
• Fontana P, Bodmer A, Gruel Y, Boehlen F, Janer V, Kaya G, Righini M. Skin necrosis is a clinical manifestation of low-molecular weight heparin-induced thrombocytopenia. Thromb Haemost 2004;91:196–197
   PubMed Web of Science ®Google Scholar
• Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: A prospective cohort study. Blood 2003;101:2955–2959
   PubMed Web of Science ®Google Scholar
• Stein PD, Hull RD, Matta F, Yaekoub AY, Liang J. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med 2009;122:919–930
   PubMed Web of Science ®Google Scholar
• Prandoni P, Siragusa S, Girolami B, Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: A prospective cohort study. Blood 2005;106:3049–3054
   PubMed Web of Science ®Google Scholar
• Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis. Blood 2005;106:2710–2715
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006;108:2937–2941
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need? J Lab Clin Med 2005;146:341–346
   PubMed Web of Science ®Google Scholar
• Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007;82:1037–1043
   PubMed Web of Science ®Google Scholar
• Oliveira GB, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, et al. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008;168:94–102
   PubMed Web of Science ®Google Scholar
• Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759–765
   PubMed Web of Science ®Google Scholar
• Cuker A, Arepally G, Crowther MA, Rice L, Datko F, Hook K, Propert KJ, Kuter DJ, Ortel TL, Konkle BA, Cines DB. The HIT Expert Probability (HEP) Score: A novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010;8:2642–2650
   PubMed Web of Science ®Google Scholar
• Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: A systematic review and meta-analysis. Blood 2012;120:4160–4167
   PubMed Web of Science ®Google Scholar
• Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: Second edition. Br J Haematol 2012;159:528–540
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Eng J Med 2007;356:2653–2655; discussion 5
   PubMed Web of Science ®Google Scholar
• Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008;99:779–781
   PubMed Web of Science ®Google Scholar
• Burch M, Cooper B. Fondaparinux-associated heparin-induced thrombocytopenia. Proc Bayl Univ Med Cent 2012;25:13–15
   PubMedGoogle Scholar
• Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH. Laboratory testing for heparin-induced thrombocytopenia: A conceptual framework and implications for diagnosis. J Thromb Haemost 2011;9:2498–2500
   PubMed Web of Science ®Google Scholar
• Smythe MA, Koerber JM, Mehta TP, Forsyth LL, Conger E, Corbets LR, Mattson JC. Assessing the impact of a heparin-induced thrombocytopenia protocol on patient management, outcomes and cost. Thromb Haemost 2012;108:992–998
   PubMed Web of Science ®Google Scholar
• Uaprasert N, Chanswangphuwana C, Akkawat B, Rojnuckarin P. Comparison of diagnostic performance of the heparin-induced thrombocytopenia expert probability and the 4Ts score in screening for heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis: Int J Haemost Thromb 2013;24:261–268
   PubMed Web of Science ®Google Scholar
• Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, Potzsch B, Klamroth R, Hankowitz J, et al. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT) – Findings from the GerHIT multi-centre registry study. Thromb Res 2014;134:29–35
   PubMed Web of Science ®Google Scholar